These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9627068)

  • 1. Effects of lidocaine and mexiletine on defibrillation energy requirements in animals treated with flecainide.
    Sato S; Imagawa N
    Resuscitation; 1998 Mar; 36(3):175-80. PubMed ID: 9627068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mexiletine has no effect on defibrillation energy requirements in dogs.
    Sato S; Tsuji MH; Naito H
    Pacing Clin Electrophysiol; 1994 Dec; 17(12 Pt 1):2279-84. PubMed ID: 7885935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
    Xue YX; Arita J; Aye NN; Hashimoto K
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):649-56. PubMed ID: 9879724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolongation of intraventricular conduction time associated with fatal [correction of fetal] impairment of defibrillation efficiency during treatment with class I antiarrhythmic agents.
    Murakawa Y; Inoue H; Kuo TT; Sezaki K; Nakajima T; Usui M; Yamashita T; Ajiki K; Oikawa N; Sugimoto T
    J Cardiovasc Pharmacol; 1995 Feb; 25(2):194-9. PubMed ID: 7752644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cutaneous analgesic effect of class I antiarrhythmic drugs.
    Tzeng JI; Cheng KI; Huang KL; Chen YW; Chu KS; Chu CC; Wang JJ
    Anesth Analg; 2007 Apr; 104(4):955-8. PubMed ID: 17377113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine.
    Kondo T; Yamaki M; Kubota I; Tachibana H; Tomoike H
    J Am Coll Cardiol; 1997 Jun; 29(7):1639-44. PubMed ID: 9180130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of flecainide on defibrillation thresholds in the anesthetized dog.
    Hernandez R; Mann DE; Breckinridge S; Williams GR; Reiter MJ
    J Am Coll Cardiol; 1989 Sep; 14(3):777-81. PubMed ID: 2504799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide.
    Pottage A
    Am J Cardiol; 1983 Sep; 52(6):24C-31C. PubMed ID: 6414279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New antiarrythmic drugs: mexiletine, tocainide, lorcainide, encainide, flecainide, propafenone, cipralan, sotalol].
    Touboul P; Kirkorian G; Atallah G; Moleur P
    Ann Cardiol Angeiol (Paris); 1982 Dec; 31(7):531-7. PubMed ID: 6820620
    [No Abstract]   [Full Text] [Related]  

  • 11. Do the effects of antiarrhythmic drugs on defibrillation efficacy vary among different shock waveforms?
    Murakawa Y; Yamashita T; Kanese Y; Omata M
    Pacing Clin Electrophysiol; 1998 Oct; 21(10):1901-8. PubMed ID: 9793086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antiarrhythmic drugs on the repetitive extrasystole threshold and the ventricular fibrillation threshold.
    Murakawa Y; Toda I; Nozaki A; Kawakubo K; Sugimoto T
    Cardiology; 1989; 76(1):58-66. PubMed ID: 2468414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of flecainide, encainide, and clofilium on ventricular refractory period extension by transcardiac shocks.
    Sweeney RJ; Gill RM; Steinberg MI; Reid PR
    Pacing Clin Electrophysiol; 1996 Jan; 19(1):50-60. PubMed ID: 8848377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shock-induced refractory period extension and pharmacologic modulation of defibrillation threshold.
    Murakawa Y; Sezaki K; Inoue H; Usui M; Yamashita T; Ajiki K; Oikawa N; Iwasawa K; Omata M
    J Cardiovasc Pharmacol; 1994 May; 23(5):822-5. PubMed ID: 7521467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation.
    Echt DS; Black JN; Barbey JT; Coxe DR; Cato E
    Circulation; 1989 May; 79(5):1106-17. PubMed ID: 2469545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency-dependent effects of several class I antiarrhythmic drugs on Vmax of action potential upstroke in canine cardiac Purkinje fibers.
    Varro A; Elharrar V; Surawicz B
    J Cardiovasc Pharmacol; 1985; 7(3):482-92. PubMed ID: 2410678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between drugs and devices: experimental and clinical studies.
    Manz M; Jung W; Lüderitz B
    Am Heart J; 1994 Apr; 127(4 Pt 2):978-84. PubMed ID: 8160602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers.
    Lu HR; Rohrbacher J; Vlaminckx E; Van Ammel K; Yan GX; Gallacher DJ
    Br J Pharmacol; 2010 May; 160(1):60-76. PubMed ID: 20331615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization.
    Osadchii OE
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):240-51. PubMed ID: 24220314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flecainide acetate does not alter the energy requirements for direct ventricular defibrillation using sequential pulse defibrillation in pigs.
    Szabo TS; Jones DL; McQuinn RL; Klein GJ
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):377-83. PubMed ID: 2465436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.